Circulating MicroRNA Profiling for Phenotypic Stratification in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Candidate-Based Study
Open Access
- 4 March 2026
- journal article
- research article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (3) , 272
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) comprises phenotypic subgroups, including type-2 diabetes-associated MAFLD (T2D-MAFLD), obesity-associated MAFLD (OB-MAFLD), and lean MAFLD (L-MAFLD). Emerging evidence indicates that dysregulation of miRNAs plays a key role in MAFLD pathogenesis and progression. This study evaluated the diagnostic accuracy of a plasma miRNA-based signature as a non-invasive biomarker for early detection and phenotypic stratification of MAFLD. A total of 393 MAFLD patients and 109 healthy controls were enrolled. Plasma expression of miR-122, miR-103a, miR-222, miR-15a, miR-34a, miR-192, miR-197, and miR-99a was quantified using Reverse transcription polymerase chain reaction. Compared to controls, MAFLD patients exhibited significant upregulation of miR-122, miR-103a, miR-222, miR-15a, and miR-34a, alongside downregulation of miR-197 and miR-99a. Multinomial logistic regression revealed phenotype-specific associations: miR-103a, miR-34a, and miR-197 with T2D-MAFLD; miR-122, miR-222, and miR-99a with OB-MAFLD; and miR-15a with L-MAFLD. Receiver operating characteristic analysis demonstrated highest individual diagnostic accuracy for miR-197 in T2D-MAFLD (AUC = 0.784), miR-99a in OB-MAFLD (AUC = 0.869), and miR-15a in L-MAFLD (AUC = 0.776). Integrating combined miRNA panels with biochemical markers further improved diagnostic performance and clinical utility, achieving high positive and negative predictive values. In conclusion, plasma miRNA signatures enable phenotype-specific discrimination of MAFLD subtypes and may serve as promising non-invasive tools pending multi-center validation.Keywords
Funding Information
- National University of Medical Sciences (02/Acct/NUMS/18/3/2021)
This publication has 46 references indexed in Scilit:
- The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver diseaseHepatology International, 2025
- MiR-103-3p promotes hepatic steatosis to aggravate nonalcoholic fatty liver disease by targeting of ACOX1Molecular Biology Reports, 2022
- High expression levels of circulating microRNA‐122 and microRNA‐222 are associated with obesity in children with Mayan ethnicityAmerican Journal of Human Biology, 2020
- Circulating miR-103 family as potential biomarkers for type 2 diabetes through targeting CAV-1 and SFRP4Acta Diabetologica, 2019
- Circulating microRNAs and adipokines as markers of metabolic syndrome in adolescents with obesityClinical Nutrition, 2019
- Circulatory miRNA biomarkers of metabolic syndromeActa Diabetologica, 2019
- miR-222 targets ACOX1, promotes triglyceride accumulation in hepatocytesHepatobiliary & Pancreatic Diseases International, 2019
- Triglyceride Metabolism in the LiverComprehensive Physiology, 2018
- Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver diseaseBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2017
- Obesity‐induced miR‐15b is linked causally to the development of insulin resistance through the repression of the insulin receptor in hepatocytesMolecular Nutrition & Food Research, 2015